The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $6.39

Today's change0.00 0.00%
Updated June 22 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $6.39

Today's change0.00 0.00%
Updated June 22 4:00 PM -4GMT. Delayed by at least 15 minutes.

Keryx Biopharmaceuticals Inc closed at (U.S.)$6.39.

Over the last five days, shares have gained 5.45% and 9.04% year to date. Shares have underperformed the S&P 500 by 10.41% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $6.39
  • High--
  • Low--
  • Bid / Ask(U.S.) $4.15 / (U.S.) $6.85
  • YTD % change+9.04%
  • Volume0
  • Average volume (10-day)1,698,573
  • Average volume (1-month)1,254,882
  • Average volume (3-month)1,388,834
  • 52-week range(U.S.) $4.03 to (U.S.) $7.80
  • Beta5.32
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.35
Updated June 22 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-387.12%

Although this company's net profit margin is negative, it is above the industry average and implies that Keryx Biopharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.47%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue121069
Total other revenue--------
Total revenue121069
Gross profit7-5-134
Total cost of revenue514196
Total operating expense35434833
Selling / general / administrative23232120
Research & development7697
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-23-34-42-24
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-23-34-42-45
Income after tax-23-34-42-45
Income tax, total0000
Net income-23-34-42-45
Total adjustments to net income--------
Net income before extra. items-23-34-42-45
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-23-34-42-45
Inc. avail. to common incl. extra. items-23-34-42-45
Diluted net income-23-34-42-45
Dilution adjustment--000
Diluted weighted average shares107106106106
Diluted EPS excluding extraordinary itemsvalue per share-0.21-0.32-0.39-0.42
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.21-0.32-0.39-0.42